musculoskeletal-joint-diseases

** This website does not use cookies **

Recommendations and Appraisals

Musculoskeletal and joint diseases

On this page you will find our appraisal documents and recommendations sorted by BNF chapter.

Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the
NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary
on nuth.nyrdtc.rxsupp@nhs.net

	Title	Documents		Decision	Date

	Actipatch^® for management of localised musculoskeletal pain	Recommendation	Appraisal	Not recommended	20/11/2018
	Etanercept Biosimilar (Benepali^®)	Recommendation	Appraisal	Recommended as a 1st line option	05/04/2016
	Extracorporeal shockwave therapy for plantar fasciitis (NETAG)	Recommendation	Appraisal	Not recommended	10/07/2012
	Infliximab biosimilars	Recommendation	Appraisal	Recommended as an option	02/06/2015
Updated 12 Aug 2020	Infliximab Subcutaneous (Remsima^®)	Recommendation	Appraisal	Recommended as an option during Covid-19 Pandemic. To be reviewed in 12 months.	12/08/2020
	Orthotic functional electrical stimulation (FES) for drop foot of neurological origin (updated)	Recommendation	Appraisal	recommended if patient fulfils specific criteria	08/09/2015
	Rituximab (MabThera^®) for severe rheumatoid arthritis (non-NICE indications) (NETAG)	Recommendation	Appraisal	Recommends rituximab in combination with methotrexate as first-line biological therapy in cases where there is an absolute contraindication to tumour necrosis factor inhibitor	11/10/2011
	Rituximab Biosimilars	Recommendation	Appraisal	Approved for use as an option.	06/06/2017
	Sequential use of TNF inhibitors for the treatment of Psoriatic Arthritis	Recommendation	Appraisal	Recommended as an option	08/09/2015

Terms and Conditions RSS Feed Archived Recommendations